Market Cap 59.56B
Revenue (ttm) 2.25B
Net Income (ttm) -278.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1,059.18
Profit Margin -12.37%
Debt to Equity Ratio 0.00
Volume 1,075,600
Avg Vol 1,094,046
Day's Range N/A - N/A
Shares Out 131.08M
Stochastic %K 68%
Beta 0.25
Analysts Strong Sell
Price Target $424.37

Company Profile

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 551 8200
Fax: 617 551 8101
Address:
675 West Kendall Street, Henri A. Termeer Square, Cambridge, United States
LiquiditySurgeon
LiquiditySurgeon Aug. 23 at 5:21 AM
$ALNY Alnylam Pharmaceuticals has a validated RNAi platform but faces pipeline execution risk and high valuations
0 · Reply
RokuInvestor
RokuInvestor Aug. 22 at 11:04 PM
$ARWR if you just bought $ALNY you would be up so much.
0 · Reply
buymoremakemore
buymoremakemore Aug. 22 at 9:26 PM
$ALNY Im out for now. 50% gain/$20,000 profit.
0 · Reply
maineamerica
maineamerica Aug. 22 at 5:29 PM
$ALNY my very expensive put is starting to run
1 · Reply
PencilNeckGeek
PencilNeckGeek Aug. 22 at 5:21 PM
$ALNY this seems overvalued here. Or am I crazy?
2 · Reply
johnnygogogo
johnnygogogo Aug. 22 at 3:50 PM
0 · Reply
CDMO
CDMO Aug. 21 at 6:53 PM
$ALNY damn it
0 · Reply
Dkll303
Dkll303 Aug. 21 at 6:47 PM
$ALNY got the wrong ticker !! John Maraganore put his stamp here You are thinking of David Schenkien and his failure and failures , Fouse and GOFF !!! At $AGIO
0 · Reply
Quantumup
Quantumup Aug. 21 at 3:41 PM
Canaccord Genuity y'day reit'd $WVE Buy/$19: $WVE plans to report updated Ph1/2 WVE-006 [ $GSK ] data from the completed SAD and MAD 200mg cohorts this Q - we think sometime in the coming weeks (followed by 400mg SAD data "in the fall" per the co). As a reminder, SAD data from the first two patients dosed was shared in Oct 2024, showing an increase in both M-AAT (6.9uM) and total AAT (10.8uM). We're expecting positive data from the MAD cohort, given co commentary around greater liver exposure and higher liver concentration of WVE-006 with the multidose. We like the risk/reward in this update and expect ~30%+ upside on good news (for reference, shares were up ~74% from ~$9 to ~$15 on the Oct 2024 update) vs. transient ~10% downside on a disappointing update. Downside protection comes from more AATD data expected in the fall as noted above, as well as data from the (wholly owned, higher TAM) WVE-007 in the obesity program coming later in the year. Reiterate BUY. $ALNY $QURE PTCT LLY NVO $VKTX
0 · Reply
MarketWarfare
MarketWarfare Aug. 21 at 2:38 PM
$ALNY this stock is pumped daily, huh? 20% haircut coming very soon. Happens all the time.
0 · Reply
Latest News on ALNY
Alnylam: Amvuttra Is Just Getting Started

Jul 31, 2025, 3:13 PM EDT - 23 days ago

Alnylam: Amvuttra Is Just Getting Started


Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Jul 1, 2025, 9:06 AM EDT - 7 weeks ago

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?


Alnylam Pharmaceuticals Names Garg R&D Chief

Jun 18, 2025, 12:04 PM EDT - 2 months ago

Alnylam Pharmaceuticals Names Garg R&D Chief


Alnylam Issues 2024 Corporate Responsibility Report

May 20, 2025, 9:00 AM EDT - 3 months ago

Alnylam Issues 2024 Corporate Responsibility Report


Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Mar 21, 2025, 5:37 PM EDT - 5 months ago

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster


Alnylam shares rise on expanded heart drug approval

Mar 21, 2025, 7:34 AM EDT - 5 months ago

Alnylam shares rise on expanded heart drug approval


US FDA approves Alnylam's drug for rare heart condition

Mar 20, 2025, 5:59 PM EDT - 5 months ago

US FDA approves Alnylam's drug for rare heart condition


Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum


Alnylam: Waiting For Regulatory Updates In March

Feb 13, 2025, 5:01 PM EST - 6 months ago

Alnylam: Waiting For Regulatory Updates In March


LiquiditySurgeon
LiquiditySurgeon Aug. 23 at 5:21 AM
$ALNY Alnylam Pharmaceuticals has a validated RNAi platform but faces pipeline execution risk and high valuations
0 · Reply
RokuInvestor
RokuInvestor Aug. 22 at 11:04 PM
$ARWR if you just bought $ALNY you would be up so much.
0 · Reply
buymoremakemore
buymoremakemore Aug. 22 at 9:26 PM
$ALNY Im out for now. 50% gain/$20,000 profit.
0 · Reply
maineamerica
maineamerica Aug. 22 at 5:29 PM
$ALNY my very expensive put is starting to run
1 · Reply
PencilNeckGeek
PencilNeckGeek Aug. 22 at 5:21 PM
$ALNY this seems overvalued here. Or am I crazy?
2 · Reply
johnnygogogo
johnnygogogo Aug. 22 at 3:50 PM
0 · Reply
CDMO
CDMO Aug. 21 at 6:53 PM
$ALNY damn it
0 · Reply
Dkll303
Dkll303 Aug. 21 at 6:47 PM
$ALNY got the wrong ticker !! John Maraganore put his stamp here You are thinking of David Schenkien and his failure and failures , Fouse and GOFF !!! At $AGIO
0 · Reply
Quantumup
Quantumup Aug. 21 at 3:41 PM
Canaccord Genuity y'day reit'd $WVE Buy/$19: $WVE plans to report updated Ph1/2 WVE-006 [ $GSK ] data from the completed SAD and MAD 200mg cohorts this Q - we think sometime in the coming weeks (followed by 400mg SAD data "in the fall" per the co). As a reminder, SAD data from the first two patients dosed was shared in Oct 2024, showing an increase in both M-AAT (6.9uM) and total AAT (10.8uM). We're expecting positive data from the MAD cohort, given co commentary around greater liver exposure and higher liver concentration of WVE-006 with the multidose. We like the risk/reward in this update and expect ~30%+ upside on good news (for reference, shares were up ~74% from ~$9 to ~$15 on the Oct 2024 update) vs. transient ~10% downside on a disappointing update. Downside protection comes from more AATD data expected in the fall as noted above, as well as data from the (wholly owned, higher TAM) WVE-007 in the obesity program coming later in the year. Reiterate BUY. $ALNY $QURE PTCT LLY NVO $VKTX
0 · Reply
MarketWarfare
MarketWarfare Aug. 21 at 2:38 PM
$ALNY this stock is pumped daily, huh? 20% haircut coming very soon. Happens all the time.
0 · Reply
PaulY123
PaulY123 Aug. 21 at 12:40 PM
Sold 60% of my $ALNY near $460. Let it cool down and revert
0 · Reply
wrengler4
wrengler4 Aug. 21 at 11:24 AM
$QURE RED …as always !!! Matt’s stock market broker buddies get info off his burner phone !!! They fcuk long Term shareholders daily , and Leerink and their brokerage ideas, put themselves in bankruptcy !! They believed $ALNY would never get approvals Guess what !!! $460 !!! From $28 ! Butt boy Berhens at Leerink , made a big error
0 · Reply
skeezbag
skeezbag Aug. 20 at 7:56 PM
$ALNY make it bleed! Make it bleed! @johnnygogogo
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 20 at 6:20 AM
$ALNY extended higher in wave ((3)) as expected and is eyeing a break above 469 soon. A larger pullback in wave ((4)) in 3, 7, or 11 swings should offer another buying opportunity against the April 2025 low #Elliottwave #Stocks
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 20 at 6:09 AM
$ALNY is rallying in wave ((3)) from the #BlueBox area, targeting the 368–469 zone in a bullish sequence explained last month See the full breakdown at https://elliottwave-forecast.com/stock-market/alny-eyes-rally-toward-368-469-zone/ #Elliottwave #Stocks
0 · Reply
skeezbag
skeezbag Aug. 19 at 7:44 PM
$ALNY oh phew it's up today. I thought 1minute was way too long to be down for this stock
1 · Reply
johnnygogogo
johnnygogogo Aug. 19 at 6:34 PM
$ALNY does anyone know anyone who’s actually still buying shares at current valuation? Or is it harvest season while the bond desk hedges keep this in place for their big conversion day?
0 · Reply
skeezbag
skeezbag Aug. 19 at 6:26 PM
$ALNY I think I saw this stock go negative on any given day over the past 3m for a while 2 minutes Cc @johnnygogogo
1 · Reply
Fingerlickengood
Fingerlickengood Aug. 19 at 12:45 AM
$CDXS $ALNY $NVO $ARWR https://www.nytimes.com/2025/02/05/business/novo-nordisk-earnings-ozempic-wegovy.html
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 19 at 12:42 AM
$CDXS From the August 14th, 2nd quarter financial results, I believe this very subtle detail could be VERY important! "The Company expects to achieve pilot scale production of GLP-grade siRNA material using the ECO Synthesis Innovation Lab in 2025." You ask. why? Can you say 'Ozempic' !? $NVO $ALNY $ARWR https://www.biospace.com/press-releases/codexis-reports-second-quarter-2025-financial-results "Ozempic is a brand name for semaglutide, a medication that belongs to the class of drugs called GLP-1 receptor agonists. It's primarily used to help manage blood sugar levels in adults with type 2 diabetes, but it's also known for its effectiveness in promoting weight loss. GLP-1 receptor agonists work by mimicking a natural hormone in the body that helps regulate blood sugar and appetite."
0 · Reply
johnnygogogo
johnnygogogo Aug. 18 at 6:26 PM
$ALNY guys, this is still cheap. $60B mkt cap vs $233B mkt cap over at Novo Nordisk. cc: @skeezbag
1 · Reply
ZManicItalian
ZManicItalian Aug. 18 at 6:18 PM
$ALNY added puts. This is way overvalued and overbought, even on the weekly charts. Plus this biotech actually has a considerable amount of debt 😬
3 · Reply